Could a common arthritis drug calm heart inflammation?

NCT ID NCT06868381

Not yet recruiting Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early trial tests whether baricitinib, an immune-calming drug already used for arthritis, can reduce heart inflammation in people with cardiac sarcoidosis. Ten adults will take the drug for 16 weeks alongside their usual steroid-sparing medication. Researchers will use PET scans to see if the inflammation in the heart gets better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: baricitinib (a drug that calms the immune system)
What this could lead to: If it works, this could point toward a new treatment option for cardiac sarcoidosis, potentially reducing heart inflammation without high-dose steroids.
What could go wrong: This is a very small, early-phase trial with only 10 people, so results may not apply to everyone. Baricitinib can also increase infection risk and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC SARCOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiac sarcoidosis sarcoidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC SARCOIDOSIS

Contacts and locations

Locations

Stanford University

Palo Alto, California, 94304-2210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.